

**Part 1 All Speakers and Planning Committee members must complete this form and submit to the planning committee. Disclosure must be made to the audience whether you do or do not have a relationship with a commercial entity such as a pharmaceutical organization, medical device company or a communications firm.**

- ☐ I do **not** have an affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Speakers who have no involvement with industry should inform the audience that they cannot identify any conflict of interest.
- ☐ I **have/had** an affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Complete the section below as it applies to you during the past two calendar years. Please indicate the commercial organization(s) with which you have/had affiliations, and briefly explain what connection you have/had with the organization. You must disclose this information to your audience.

		Company/Organization	Details
<b>A</b>	I am a member of an Advisory Board or equivalent with a commercial organization.	Merck, Neurocrine, Supernus, Otsuka, Sunovion	
<b>B</b>	I am a member of a Speakers bureau.		
<b>C</b>	I have received payment from a commercial organization. (including gifts or other consideration or 'in kind' compensation)		
<b>D</b>	I have received a grant(s) or an honorarium from a commercial organization.	Merck, Neurocrine, Otsuka, Teva, Sunovion, Takeda, Lundbeck, Vanda	
<b>E</b>	I hold a patent for a product referred to in the CME/CPD program or that is marketed by a commercial organization.		
<b>F</b>	I hold investments in a pharmaceutical organization, medical devices company or communications firm.		
<b>G</b>	I am currently participating in or have participated in a clinical trial within the past two years.		

**Part 2 Speakers only:**

	Yes	No	
<b>H</b>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).
<b>I</b>			The Royal College requires faculty presentations to be consistent in their use of either generic names or both generic and trade names during their presentation.

Check one: ☒ **Faculty/Speaker** ☐ **Planning Committee Member**

**Activity Title: Treating the Mind, Respecting the Body: Clinical Considerations and Patient Centricity in the Management of Bipolar Disorder**

**Acknowledgment: I, Dr. Joseph Goldberg, acknowledge that the above information is accurate and I understand that this information will be publicly available.**

**Signature:**



**Date:**

October 13, 2017